Denosumab Treatment for Fibrous Dysplasia

Alison M Boyce,1,2 William H Chong,1 Jack Yao,3 Rachel I Gafni,1 Marilyn H Kelly,1 Christine E Chamberlain,4 Carol Bassim,5 Natasha Cherman,1 Michelle Ellsworth,6 Josephine Z Kasa-Vubu,6 Frances A Farley,6 Alfredo A Molinolo,7 Nisan Bhattacharyya,1 and Michael T Collins1

1Skeletal Clinical Studies Unit, Craniofacial and Skeletal Diseases Branch (CSDB), National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, MD, USA
2National Institute of Child Health and Development (NICHD), National Institutes of Health (NIH), Bethesda, MD, USA
3Radiology and Imaging Sciences, National Institutes of Health (NIH), Bethesda, MD, USA
4Pharmacy Department, National Institutes of Health (NIH), Bethesda, MD, USA
5National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, MD, USA
6University of Michigan Health Systems, University of Michigan, Ann Arbor, MI, USA
7Oral and Pharyngeal Cancer Branch, National Institute of Dental and Craniofacial Research (NIDCR), National Institutes of Health (NIH), Bethesda, MD, USA

ABSTRACT

Fibrous dysplasia (FD) is a skeletal disease caused by somatic activating mutations of the cyclic adenosine monophosphate (cAMP)-regulating protein, α-subunit of the Gs stimulatory protein (Gsα). These mutations lead to replacement of normal bone by proliferative osteogenic precursors, resulting in deformity, fracture, and pain. Medical treatment has been ineffective in altering the disease course. Receptor activator of NF-κB ligand (RANKL) is a cell-surface protein involved in many cellular processes, including osteoclastogenesis, and is reported to be overexpressed in FD-like bone cells. Denosumab is a humanized monoclonal antibody to RANKL approved for treatment of osteoporosis and prevention of skeletal-related events from bone metastases. We present the case of a 9-year-old boy with severe FD who was treated with denosumab for a rapidly expanding femoral lesion. Immunohistochemical staining on a pretreatment bone biopsy specimen revealed marked RANKL expression. He was started on monthly denosumab, with an initial starting dose of 1 mg/kg and planned 0.25 mg/kg dose escalations every 3 months. Over 7 months of treatment he showed marked reduction in pain, bone turnover markers (BTMs), and tumor growth rate. Denosumab did not appear to impair healing of a femoral fracture that occurred while on treatment. With initiation of treatment he developed hypophosphatemia and secondary hyperparathyroidism, necessitating supplementation with phosphorus, calcium, and calcitriol. BTMs showed rapid and sustained suppression. With discontinuation there was rapid and dramatic rebound of BTMs with cross-linked C-telopeptide (reflecting osteoclast activity) exceeding pretreatment levels, accompanied by severe hypercalcemia. In this child, denosumab lead to dramatic reduction of FD expansion and FD-related bone pain. Denosumab was associated with clinically significant disturbances of mineral metabolism both while on treatment and after discontinuation. Denosumab treatment of FD warrants further study to confirm efficacy and determine potential morbidity, as well as to determine the mechanism of RANKL in the pathogenesis of FD and related bone marrow stromal cell diseases. © 2012 American Society for Bone and Mineral Research.

KEY WORDS: RANK LIGAND; MCCUNE-ALBRIGHT SYNDROME; HYPERCALCEMIA

Introduction

Fibrous dysplasia (FD; OMIM 174800) is an uncommon skeletal disorder in which normal bone and bone marrow are replaced by fibro-osseous tissue, leading to fracture, functional impairment, deformity, and pain.1–3 FD may occur in association with cutaneous hyperpigmentation and hyperfunctioning endocrinopathies, including hyperthyroidism, precocious puberty, growth hormone excess, and Cushing syndrome.4–6 Skeletal lesions produce excess fibroblast growth factor 23 (FGF23), leading to renal phosphate wasting, hypophosphatemia, and rickets/osteomalacia in individuals with high disease burden.7,8 FD in combination with one or more extraskeletal manifestations is termed McCune-Albright syndrome (MAS).

Received in original form January 10, 2012; revised form February 6, 2012; accepted February 23, 2012. Published online March 19, 2012.
Address correspondence to: Michael T Collins, MD, Chief, Skeletal Clinical Studies Unit, CSDB, NIDCR, NIH, 30 Convent Drive, Building 30, Room 228, MSC 4320, Bethesda, MD 20892-4320, USA. E-mail: mc247k@nih.gov
DOI: 10.1002/jbmr.1603
© 2012 American Society for Bone and Mineral Research
FD/MAS arises from activating missense mutations of the GNAS gene, which encodes the α-subunit of the Gs stimulatory protein (Gsα). Mutations occur postzygotically, resulting in a mosaic pattern of disease. There is wide variability in both the combination of tissues involved and the extent of involvement of affected tissue, likely arising from the fate of the specific clones that harbor the mutation at the outset. At the cellular level, constitutive Gsα activation leads to increased activity of adenylyl cyclase and excess production of intracellular cyclic adenosine monophosphate (cAMP). In bone, the down-stream effects of constitutively elevated Gsα lead to an inhibition of differentiation and proliferation of bone marrow stromal cells (BMSCs). Normal bone is replaced with functionally and structurally abnormal matrix, and marrow spaces show extensive fibrosis with local loss of hematopoiesis. Recently, human skeletal progenitor cells stably transfected with the FD-causing R201C Gsα mutation were shown to dramatically upregulate receptor activator of NF-κB ligand (RANKL) expression, consistent with the increased levels of osteoclastogenesis observed in FD lesions in vivo.

Current medical treatment for FD is palliative. Surgery is often necessary to mediate deformity and fracture, but is frequently ineffective in the setting of severe disease. Studies in bisphosphonates have shown consistent improvements in FD-related bone pain, but variable radiographic effects and no apparent long-term benefit on overall clinical outcomes. Additional placebo-controlled trials are needed to further define the role of bisphosphonates in treatment of FD; however, at present their primary indication is limited to relief of FD-related pain.

Denosumab is a fully-humanized monoclonal antibody to RANKL recently approved for treatment of osteoporosis and skeletal-related events in adults with bone metastases from solid tumors. RANKL is expressed by osteogenic cells including osteoblasts, and plays a key role in osteoclastogenesis. By binding to its receptor on osteoclast progenitor membranes, RANKL promotes osteoclast differentiation and ultimately leads to increased bone resorption. In addition to its role in osteoclastogenesis, RANKL also plays a role in tumorigenesis in both nonskeletal and skeletal tissues. Recent evidence suggests that the development of skeletal neoplasms depends upon activation of both RANKL and the cAMP/protein kinase A. RANKL inhibition via denosumab has recently been shown to be effective in treatment of giant cell granulomas of bone, which like FD are derived from BMSCs.

Based upon lines of evidence presented above, RANKL inhibition holds promise as a potential medical therapy for FD. We present the case of a child with FD treated with denosumab.

**Patient and Methods**

**Clinical course**

A 9-year-old boy presented with extensive polyostotic FD, hyperthyroidism, abnormalities on testicular ultrasound and café-au-lait macules, consistent with the diagnosis of MAS. The FD in his right femur underwent a dramatic expansion over an approximate 4-year period (Fig. 1). He was treated with pamidronate for 1 year, which failed to slow expansion or relieve associated bone pain. Femoral expansion was associated with significant functional impairment, pain, and tachycardia from increased cardiac output. At 8 years of age he underwent a disarticulation amputation at the level of the femur-iliac joint. Several months later the FD in his left femur began a similar dramatic expansion, associated with significant bone pain requiring daily narcotic use. A second disarticulation amputation of his remaining lower extremity was planned. The patient’s mother contacted the research team with hope that a treatment might prevent the need for amputation.

A 12-month course of denosumab was planned in an attempt to slow femoral expansion (Fig. 2A). The protocol was approved by the Institutional Review Board of the NIDCR, and informed assent and consent were obtained from the patient and his mother. Denosumab was to be given once monthly, with an initial starting dose of 1 mg/kg. Dose escalations were planned at 3-month intervals to 1.25 mg/kg, 1.5 mg/kg, and 1.75 mg/kg, respectively. The starting dose was chosen as a dose intermediate between the dose used to treat osteoporosis (approximately 0.9 mg/kg every 6 months) and the dose used to treat giant cell tumor of bone (1.7 mg/kg once monthly).

After 7 months of treatment the patient fell out of bed at home and fractured his femur. The fracture occurred at the distal end of an intramedullary rod, which served as a stress riser and a predisposing site for fracture (Fig. 3A). Due to a theoretical risk of delayed fracture healing, the eighth dose of denosumab was held. Shortly thereafter the patient’s family lost contact with the research team.
Fig. 2. Proposed treatment regimen and clinical course. (A) Proposed regimen. Dosing regimen and monitoring schedule are indicated. Denosumab was to be given monthly at an initial dose of 1 mg/kg. Dose escalations were planned at 3-month intervals (arrows) to 1.25 mg/kg, 1.5 mg/kg, and 1.75 mg/kg. The patient was evaluated by his local endocrinologist monthly and at NIH every 3 months. Mineral panels were monitored weekly for the first 3 months and then monthly (not shown). Bone turnover markers were monitored monthly (not shown). The scale represents months. D = dose of denosumab; TV = tumor volume; AS = arm span; XR = hand XR; DE = dental exam; BX = bone biopsy. (B) Clinical course. The periods for the administration of analgesics, supplemental phosphorus, calcium and calcitriol, denosumab, and bisphosphonate treatment (pamidronate or zoledronic acid) are indicated by the transverse lines, and cessation by the double vertical lines. Time points for biopsy, fracture and start of hypercalcemia are indicated. The scale represents months.

Fig. 3. Radiographs. (A) A radiograph at the time of fracture indicated the fracture occurred at the distal end of a previously inserted intramedullary rod (arrow). (B) Radiograph taken 8 weeks after plate fixation shows callus formation at the fracture site (arrow). (C,D) Knee radiographs pretreatment and 6 months after the initiation of treatment, as indicated. (E,F) Hand radiographs, as above. Note the thick sclerotic bands at the level of the metaphyses in panels D and F (arrows), reminiscent of the radiologic appearance of children treated with bisphosphonates. There does not appear to be evidence of frank rickets.
Endpoints

The primary endpoint of denosumab efficacy was the rate of change in tumor volume as measured by CT. Additional efficacy endpoints were bone turnover markers (BTMs) and pain. Safety endpoints were signs and symptoms of infection, effects on dentition, and linear growth. Endpoints were assessed as indicated in Fig. 2.

Lesion volume was assessed by a semiautomatic approach using a Vitrea workstation (Vital Images Inc., Minnetonka, MN, USA). An operator first placed a seed point inside the center of the lesion. The computer program then learned the intensity and texture pattern in the vicinity of the seed point and expanded the region three-dimensionally to include pixels with similar intensity and texture as that within the lesion. The lesion region was then smoothed to close gaps and form a solid three-dimensional (3D) object. The volume of the lesion was obtained by counting the pixels inside the 3D object.

BTMs were measured for the formation marker procollagen type 1 amino-terminal propeptide (P1NP; Radioimmunoassay, Mayo Medical Laboratories) and the resorption marker beta cross-laps of type I collagen c-telopeptide-related fraction (B-CTX; Electrochemiluminescence Immunoassay, Mayo Medical Laboratories). Arm span was measured as a surrogate for linear growth. Dental examinations, which included dental panoramic and selected periapical radiographs to determine dental development and morphology, were performed at baseline and after 3 months of treatment.

RANKL immunohistochemistry was performed on paraffin-embedded sections. Sections were deparaffinized and antigen retrieval was performed using a heat-induced sodium citrate buffer method. Primary antibody reaction was performed using a monoclonal anti-RANKL antibody (Novus Biologicals, Littleton, CO, USA; NB 100-56512) at 1 to 200 dilution incubated overnight at 4°C. Sections were then washed and incubated successfully with the biotinylated secondary antibody (Vector Laboratories, Burlingame, CA, USA; BA-9200) at 1 to 400 dilution for 30 minutes at room temperature. VECTASTAIN ABC method (Vector Laboratories; PK-4000) was used and the slides were then developed under direct microscopic visualization using Sigma-Aldrich SIGMAFAST 3,3'-diaminobenzidine (Sigma-Aldrich Corp., St. Louis, MO, USA; D4168).

G_{\alpha} mutation testing was performed on BMSCs obtained from a bone biopsy prior to treatment with denosumab. Single colonies of cells were grown separately and total DNA was isolated using Wizard genomic DNA isolation kit (Promega, WI, USA). DNA from multiple colonies was PCR-amplified and sequenced for subsequent G_{\alpha} genotyping. Total DNA was isolated from individual BMSC colonies and used for amplification reactions to enrich for the G_{\alpha}-specific genomic regions using two specific oligonucleotides: 5’-TGACTATGTGCCGAGGAGAT-3’ and 5’-CCACGTCAACATGCTGGTG-3’. PCR products were gel purified and were subsequently sequenced.

Results

Tumor volume

Tumor volume was assessed at four time points: 13.5 months prior to initiation of denosumab, at the initiation of denosumab treatment, and after 3 and 9 months of treatment. The volume of FD in the left femur increased 57% between the initial scan and the scan done at the start of denosumab (Fig. 4). Assuming a linear rate of expansion over this 13.5-month period, tumor volume increased at a rate of 4.2% per month. However, per report of the patient’s mother and orthopedic surgeon, the expansion began acutely and progressed rapidly over a 6-week period immediately preceding the initiation of denosumab. Assuming the tumor growth occurred during this 1.5-month period, tumor volume increased at a rate of 37.7% per month. The rate of tumor growth was additionally calculated after 3 and 9 months of treatment. During these intervals the rate of growth was 1.4% per month and 0.56% per month, respectively (Fig. 4C).

Additional endpoints

BTMs were significantly elevated at baseline, declined dramatically after the first dose of denosumab, and remained suppressed.

Fig. 4. Tumor volume. (A) A representative two-dimensional image created from a horizontal slice prior to denosumab treatment at the level of the femoral head taken from a thin-slice CT study that was used to measure tumor volume (see Patient and Methods). (B) A similar image taken 2 months after the final dose of denosumab. (C) The change in tumor volume over time. The first and last time points were derived from the studies done for A and B. The start of denosumab treatment is indicated. There were 13.5 months between the initial study and the scan done prior to start of denosumab. The solid line represents the change in volume assuming a linear rate of growth. Per report of the patient’s mother and orthopedic surgeon, expansion began acutely and progressed rapidly over 6 weeks prior to initiation of denosumab, represented by the dashed line. Initiation of treatment was associated with marked decrease in the rate of tumor growth.
throughout the duration of treatment (Fig. 5A, B). Narcotic-requiring pain diminished dramatically after initiation of denosumab. After one dose the patient was able to discontinue narcotics in favor of ibuprofen, and after three doses was able to stop analgesics altogether (Fig. 2). A dental exam was done at baseline and 3 months after the start of denosumab treatment. At baseline, healthy and normal dentition with mild dental developmental delay was noted, and at follow-up, no deleterious effects were seen. Hand radiographs were monitored every 3 months to assess for tubulation defects and deleterious effects on the growth plate. The shapes of the bones were preserved, and there were no obvious signs of rickets; however, the patient developed thick sclerotic bands at the level of the metaphyses (Fig. 3C–F).

A bone biopsy was obtained prior to treatment start, and revealed sections of typical fibrous tissue and woven bone, but also a striking abundance of cartilage that accounted for most of the tissue in many sections. Osteoclasts were rare (Fig. 6A, B). Immunohistochemical staining was markedly positive for RANKL (Fig. 6C). Sequencing of DNA extracted from biopsy tissue and PCR-amplified revealed a typical mutation in exon 8 of GNAS that resulted in substitution of histidine for arginine at amino acid position 201 (R201H) (Fig. 7).

The patient became hypophosphatemic with secondary hyperparathyroidism shortly after receiving the first dose of denosumab, necessitating supplementation with phosphorus, calcitriol, and calcium. Blood phosphorus and calcium levels are shown in Fig. 5C, D.

The patient underwent plate fixation of the left femur, and a second biopsy specimen was obtained. The orthopedic surgeon (FAF) reported the quality of the bone appeared to be subjectively improved as compared to before denosumab treatment. Samples were taken at the time of the surgery, but the specimens were taken from areas of cortical bone and comparison to pretreatment sections was not informative. Radiographs taken 4 weeks after fixation showed callus formation at the fracture site (Fig. 3B), and plans were being made to resume denosumab, but due to unforeseen social issues the patient was temporarily lost to follow-up.

Response to cessation of denosumab

Two months after the fracture and cessation of denosumab, the patient presented to his local emergency department with 5 days of vomiting. Laboratory results revealed severe hypercalcemia with a level of 4.5 mmol/L (18 mg/dL) (normal 2.1–2.6 mmol/L). Phosphorus and creatinine were normal, and parathyroid hormone (PTH), parathyroid hormone–related protein (PTHrP), and 1,25-vitamin D were suppressed. BTMs were extremely elevated. P1NP had returned to approximately baseline levels, but B-CTX had rebounded to a level approximately 2.5-fold above the pretreatment level (Fig. 5A, B).

The patient was admitted to the hospital and treated with IV hydration, calcitonin, and pamidronate. Calcium levels improved, but he remained mildly hypercalcemic as an outpatient, necessitating repeated treatment with intravenous bisphosphonates (pamidronate or zoledronic acid). BTMs gradually returned to baseline after approximately 5 months (146 days) following denosumab discontinuation, after which the hypercalcemia resolved.

Fig. 5. Biochemical response to treatment. (A) Serum B-CTX, a marker of bone resorption. (B) Serum P1NP, a marker of bone formation. (C) Serum calcium. (D) Serum phosphorus. Denosumab was initiated at day 0 and discontinued at day 210, indicated by the arrows. After discontinuation of denosumab there was a marked increase in BTMs, especially the resorption marker CTX, which was associated with marked hypercalcemia in the presence of a suppressed serum PTH, and 1,25(OH)2 vitamin D. Normal ranges for calcium and phosphorus are indicated by boxes. Normal ranges for CTX and P1NP in children are not well defined.
In this child with a rapidly expanding FD lesion, treatment with denosumab was associated with a marked decrease in the rate of tumor growth. Expansion of FD at this rate is a rare but potentially devastating complication. Currently no medical therapies are capable of altering the disease course of FD, which makes this child’s response to RANKL inhibition of particular interest. The mechanism by which this effect occurred is not clear. The accepted mechanism of action of denosumab in the treatment of osteoporosis is inhibition of osteoclastogenesis by disruption of stromal cell/osteoblast–osteoclast RANK–RANKL interaction. This may have been operative here, as osteoclastic resorption of normal bone adjacent to FD is likely involved in lesion expansion. In rapidly expanding lesions such as this, stromal cell proliferation is likely the more important mechanism of expansion. In osteoporosis, inhibition of osteoclastogenesis is also accompanied by a concomitant and parallel inhibition of bone formation, as evidenced by the marked decrease in markers of bone formation, and marked inhibition of bone formation as seen by histomorphometry.(23,33) In denosumab treatment of giant cell granulomas, which like FD are tumors composed primarily of fibroblast-like cells of BMSC lineage, there is also inhibition of tumor growth.(32) Additionally, RANKL inhibition has been shown to have direct inhibitory effects on other tumors such as breast cancer.(24,25) Taken together, these data suggest that denosumab treatment of FD may have direct effects (or possibly indirect effects mediated by an as yet unidentified osteoclast-derived factor) on the proliferating bone marrow stromal-derived cells that dominate FD lesions.

Although promising, whether the response to denosumab seen in this child will be replicated in other individuals with FD remains to be seen. His presentation was atypical in both the growth pattern (rapid onset and marked expansion), and histologically. Specimens from both the amputated right leg (not shown) and the lesion monitored during treatment revealed large areas of cartilaginous tissue and a relative paucity of osteoclasts. Although small cartilaginous foci are not uncommon in FD, extensive cartilaginous proliferation as seen here is a rare but previously-described phenomenon.(34–36) The demonstration of a typical GNAS mutation in this lesion, the first time this has been demonstrated in this variant of FD, confirms that this molecular defect is at least partially responsible for the
phenotype. However, the prominence of cartilage seen in this specimen clearly marks the FD in this patient as atypical. Whether or not denosumab will have similar efficacy in typical FD is not known; the fact that RANKL expression is prominent in a model of FD and that RANKL expression, as seen by immunohistochemistry, can be seen in more histologically typical FD lesions (personal observations, MTC), is encouraging that it may.

The pretreatment rate of growth in this child was an estimate based upon a combination of imaging data and observations of the patient’s mother and orthopedist. This resulted in a degree of uncertainty in determining the exact rate of growth and the precise effect of denosumab treatment on the rate of growth. Although it is possible that the lesion had undergone a significant but time-limited period of expansion, and that the initiation of denosumab was coincidental, this is probably less likely than the possibility that denosumab had a direct effect on lesion expansion. An effect by denosumab is supported by what occurred in the right femur; ie, rapid and progressive expansion until amputation. Additional studies are needed to assess potential efficacy in FD.

Important and potentially serious side effects occurred as a result of treatment with denosumab: secondary hyperparathyroidism and hypophosphatemia during denosumab treatment, and severe hypercalcemia on discontinuation. The likely cause of secondary hyperparathyroidism was combined inhibition of osteoclast mediated calcium release from bone and FGF23-mediated suppression of 1,25-(OH)2-vitamin D generation. As is seen in extensive FD, serum FGF23 was elevated at 95.5 pg/mL (normal 20–50 pg/mL), but FGF23 levels did not change significantly throughout treatment. However, upon discontinuation of denosumab there was a marked rebound in BTMs (CTX rose to 2.5-fold greater than the pretreatment levels), with a proportionally greater rebound in the resorption marker CTX than the formation marker P1NP. BTM levels peaked at approximately 90 days after denosumab discontinuation, and returned to pretreatment levels after 146 days (approximately 5 months). Although a similar pattern of changes in BTMs has been seen in patients with osteoporosis, there are important differences. Relative to patients with osteoporosis, there was a similar marked and pronounced decline in both resorption and formation markers. However upon discontinuation the rebound was more rapid in this patient (3 months versus 6 months), the rebound to levels above baseline was confined to the resorption marker, the level of resorption marker rebound was much greater (250% versus 60%), and the return to baseline was much shorter (5 months versus 24 months). Of note, the rapidity of return to baseline in this child was enhanced by treatment with bisphosphonates. Hypercalcemia has not been previously reported in association with denosumab discontinuation in osteoporosis studies in which follow-up has been continued for relatively long periods. Although hypercalcemia after denosumab discontinuation has not been reported in cancer studies, in which the doses are higher, adverse event monitoring is not as long as the follow-up in osteoporosis studies. The marked rebound seen in this patient may be due to some combination of very active FD and a higher rate of bone metabolism in a growing child. Due to the severity of the associated adverse effects, practitioners should be cautious in using denosumab in patients with FD, and should consider limiting use to clinical trials and in individuals with extremely severe disease.

Preclinical studies with denosumab in rodents and primates demonstrated a significant inhibitory effect on linear growth and tooth eruption. In our patient there was no increase in arm span over a 6-month period, which may represent impaired linear growth as a complication of treatment. However, 6 months is possibly too short of a period of time for determination of growth velocity, and measurement of arm span in this patient was technically difficult due to pain and impaired mobility. The increase in primary spongiosa at the level of the epiphyses that was observed as an area of sclerosis on the radiographs suggests that growth was occurring. Nonetheless, growth impairment should be monitored as a potential adverse effect of denosumab in children. Hand and knee X-rays showed no clear impairment in bone tubulation or geometry during the treatment period; however, thick sclerotic bands developed at the level of the metaphyses, consistent with profound suppression in bone turnover. These findings are similar to those seen in children treated with bisphosphonates and represent accumulation of calcified cartilage from bisphosphonate-induced inhibition of periepiphyseal cartilage resorption.

Although the femoral fracture that occurred while on treatment was traumatic in nature, a contributory role of denosumab treatment cannot be excluded. Atypical femur fractures have been reported with antiresorptive treatment, however, this typically only occurs after years of treatment. In addition, fractures are a known complication of FD, and this patient had sustained two previous FD-related femoral fractures prior to treatment with denosumab. Consistent with what has been seen in preclinical studies with denosumab, there was no apparent disruption of fracture healing.

Conclusions

In this child with FD, denosumab was effective for both prevention of lesion expansion and FD-related bone pain. Denosumab treatment was associated with predictable, clinically significant side effects both during treatment (hypophosphatemia and secondary hyperparathyroidism) and on discontinuation (hypercalcemia) that necessitated careful monitoring and additional medications both during treatment and upon discontinuation. Denosumab treatment of FD warrants further study, not only to confirm efficacy and determine potential morbidity, but also to study the mechanism of RANKL in the pathogenesis of FD and related BMSC diseases.

Disclosures

All authors state that they have no conflicts of interest.

Acknowledgments

This research was supported by the Intramural Research Program of the NIH, NIDCR.
Authors’ roles: Study design: AMB, RIG, and MTC. Study conduct: AMB, RIG, MHK, CEC, ME, JZK, and MTC. Data collection: AMB, WHC, JY, MHK, CEC, CB, NC, ME, JZK, FAF, AAM, NB, and MTC. Data analysis: AMB, WHC, JY, CB, NC, FAF, AAM, NB, and MTC. Data interpretation: AMB, WHC, CB, NC, FAF, AAM, NB, and MTC. Drafting manuscript: AMB, WHC, JY, CB, NB, and MTC. Revising manuscript content: AMB, WHC, JY, CB, AAM, NB, and MTC. Approving final version of manuscript: AMB, WHC, JY, CB, NC, FAF, AAM, NB, and MTC. AMB and MTC take responsibility for the integrity of the data analysis.

References

3. Lichtenstein L, Jaffe HL. Fibrous dysplasia of bone: a condition affecting one, several or many bones, the graver cases of which may present abnormal pigmentation of skin, premature sexual development, hyperthyroidism or still other extraskeletal abnormalities. Arch Pathol. 1942;33:777–816.


